Experimental cell therapy aims to control devastating blood cancer in young patients
NCT ID NCT06934382
Summary
This early-stage study is testing the safety and effectiveness of an experimental cell therapy called BEAM-201 for children and young adults (ages 0-29) whose T-cell leukemia or lymphoma has returned or not responded to standard treatments. BEAM-201 is a type of CAR-T therapy, where a patient's own immune cells are modified in a lab to better find and fight cancer cells. The main goals are to find a safe dose and see if the treatment can put the cancer into remission, potentially making patients eligible for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.